Perspectives on the potential application of microRNAs in the diagnosis and treatment of triple-negative breast cancer

Abstract

Triple-negative breast cancer (TNBC) is currently the most heterogeneous and aggressive breast cancer type. It has a high recurrence rate, poor clinical prospects, and lack of predictive markers and potential treatment options. Dysregulated microRNAs (miRNAs) are involved in various cellular processes in TNBC. Moreover, variations in the miRNA levels in TNBC may act as a dependable indicator for predicting the effectiveness and specificity of treatments. Currently, the application of miRNAs for breast cancer therapy is primarily in the preclinical stage, with a focus on identifying highly specific and sensitive miRNAs that could offer new possibilities for early diagnosis, clinical treatment, and prognostic monitoring of TNBC.